Literature DB >> 11162573

Effects of troglitazone on cellular differentiation, insulin signaling, and glucose metabolism in cultured human skeletal muscle cells.

C Kausch1, J Krützfeldt, A Witke, A Rettig, O Bachmann, K Rett, S Matthaei, F Machicao, H U Häring, M Stumvoll.   

Abstract

To determine the immediate effect of thiazolidinediones on human skeletal muscle, differentiated human myotubes were acutely (1 day) and myoblasts chronically (during the differentiation process) treated with troglitazone (TGZ). Chronic TGZ treatment resulted in loss of the typical multinucleated phenotype. The increase of muscle markers typically observed during differentiation was suppressed, while adipocyte markers increased markedly. Chronic TGZ treatment increased insulin-stimulated phosphatidylinositol (PI) 3-kinase activity and membranous protein kinase B/Akt (PKB/Akt) Ser-473 phosphorylation more than 4-fold. Phosphorylation of p42/44 mitogen-activated protein kinase (42/44 MAPK/ERK) was unaltered. Basal glucose uptake as well as both basal and insulin-stimulated glycogen synthesis increased approximately 1.6- and approximately 2.5-fold after chronic TGZ treatment, respectively. A 2-fold stimulation of PI 3-kinase but no other significant TGZ effect was found after acute TGZ treatment. In conclusion, chronic TGZ treatment inhibited myogenic differentiation of that human muscle while inducing adipocyte-specific gene expression. The effects of chronic TGZ treatment on basal glucose transport may in part be secondary to this transdifferentiation. The enhancing effect on PI 3-kinase and PKB/Akt involved in both differentiation and glycogen synthesis appears to be pivotal in the cellular action of TGZ. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11162573     DOI: 10.1006/bbrc.2000.4216

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

1.  Rosiglitazone modifies the adipogenic potential of human muscle satellite cells.

Authors:  P De Coppi; G Milan; A Scarda; L Boldrin; C Centobene; M Piccoli; M Pozzobon; C Pilon; C Pagano; P Gamba; R Vettor
Journal:  Diabetologia       Date:  2006-06-24       Impact factor: 10.122

2.  ShRNA-mediated gene silencing of lipoprotein lipase improves insulin sensitivity in L6 skeletal muscle cells.

Authors:  Majib Jan; Jheem D Medh
Journal:  Biochem Biophys Res Commun       Date:  2015-04-27       Impact factor: 3.575

3.  Differences in troglitazone action on glucose metabolism in freshly isolated vs long-term incubated rat skeletal muscle.

Authors:  Florian Gras; Barbara Brunmair; Michael Roden; Werner Waldhäusl; Clemens Fürnsinn
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

4.  Enhanced insulin-stimulated glycogen synthesis in response to insulin, metformin or rosiglitazone is associated with increased mRNA expression of GLUT4 and peroxisomal proliferator activator receptor gamma co-activator 1.

Authors:  L Al-Khalili; M Forsgren; K Kannisto; J R Zierath; F Lönnqvist; A Krook
Journal:  Diabetologia       Date:  2005-04-30       Impact factor: 10.122

5.  Antidiabetic Activities of Abutilon indicum (L.) Sweet Are Mediated by Enhancement of Adipocyte Differentiation and Activation of the GLUT1 Promoter.

Authors:  Chutwadee Krisanapun; Seong-Ho Lee; Penchom Peungvicha; Rungravi Temsiririrkkul; Seung Joon Baek
Journal:  Evid Based Complement Alternat Med       Date:  2011-02-17       Impact factor: 2.629

6.  S-adenosylmethionine-induced adipogenesis is accompanied by suppression of Wnt/β-catenin and Hedgehog signaling pathways.

Authors:  Yang Liu; Wentao Lv; Boyang Yu; Tingting Ju; Feiyun Yang; Meihua Jiang; Zuohua Liu; Ling Xu; Wenjuan Sun; Jinxiu Huang; Defa Li; Jingdong Yin
Journal:  Mol Cell Biochem       Date:  2013-07-30       Impact factor: 3.396

Review 7.  PPAR gamma and human metabolic disease.

Authors:  Robert K Semple; V Krishna K Chatterjee; Stephen O'Rahilly
Journal:  J Clin Invest       Date:  2006-03       Impact factor: 14.808

8.  Type II diabetes mellitus and cardiovascular risk factors: Current therapeutic approaches.

Authors:  Christos Kalofoutis; Christina Piperi; Anastasios Kalofoutis; Fred Harris; David Phoenix; Jaipaul Singh
Journal:  Exp Clin Cardiol       Date:  2007

9.  Thiazolidinediones (PPARgamma ligands) increase IRS-1, UCP-2 and C/EBPalpha expression, but not transdifferentiation, in L6 muscle cells.

Authors:  A Hammarstedt; U Smith
Journal:  Diabetologia       Date:  2003-01-03       Impact factor: 10.122

10.  'Striking the Right Balance' in Targeting PPARgamma in the Metabolic Syndrome: Novel Insights from Human Genetic Studies.

Authors:  Mark Gurnell
Journal:  PPAR Res       Date:  2007       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.